Chronic hepatitis C genotype 1 virus: who should wait for treatment?

ABSTRACT: Elucidation of the natural history of chronic hepatitis C (CHC) and the identification of risk factors for its progression to advanced liver disease have allowed many physicians to recommend deferral treatment (triple therapy) in favour of waiting for new drug availability for patients who are at low risk of progression to significant liver disease. Newer generation drugs are currently under development, and are expected to feature improved efficacy and safety profiles, as well as less complex and shorter duration delivery regimens, compared to the current standards of care. In addition, patients with cirrhosis and prior null responders have a low rate (around 15%) of achieving sustained virological response (SVR) with triple therapy, and physicians must also consider the decision to wait

SUBMITTER: Tovo CV 

PROVIDER: S-EPMC3961974 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature